Foghorn Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
About Foghorn Therapeutics
Pharmaceutical Preparations, SIC 2834
Foghorn is a clinical-stage biotechnology enterprise that develops precision therapeutics designed to treat serious diseases, primarily cancers. The company targets the chromatin regulatory system to correct aberrant gene expression orchestrating disease progression. Leveraging its proprietary Gene Traffic Control platform, Foghorn identifies genetically determined dependencies within diseased cells to discover and design small molecule drug candidates, such as enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Its lead candidate, FHD-909, is an orally administered selective SMARCA2 inhibitor undergoing Phase 1 clinical testing for non-small cell lung cancer and solid tumors in collaboration with Eli Lilly and Company.
The company advances multiple preclinical and clinical programs across several oncology targets, including SMARCA2, CBP, EP300, and ARID1B. Foghorn conducts its operations with a workforce of 106 employees as of late 2025. It maintains collaborative research, development, and commercialization agreements covering the United States market. The provided text does not disclose the location of the company's headquarters or other geographic facilities.
Summary of the business section of Foghorn Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Foghorn Therapeutics Inc.
- Headquarters
- Cambridge, MA
- Address
- 500 Technology Square, Suite 700 02139
- Phone
- (617) 586-3100
- Employees
- 106, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte& Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- FHTX
- Exchange
- Nasdaq
- IPO date
- Oct 23, 2020
- Shares outstanding
- 59M, Jul 31, 2026
- Public float
- $172.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1822462
- CUSIP
- 344174107
- ISIN
- US3441741077
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adrian Gottschalk | Chief Executive Officer, Director | 511,704 |
| Ryan D. Maynard | Chief Financial Officer | – |
| Anna Rivkin | Chief Business Officer | – |
| Michael LaCascia | Chief Legal Officer | – |
| Alfonso Quintas Cardama | Chief Medical Officer | – |
| Steven F. Bellon | Chief Scientific Officer | 151,957 |
| Carlos Costa | Chief People Officer | 0 |
| Kristian Humer | Chief Financial Officer | – |
| Ian F. Smith | Director | 72,072 |
| B. Lynne Parshall | Director | – |
| Douglas G. Cole | Director | – |
| Scott Biller | Director | – |
| Thomas J. Lynch Jr. | Director | – |
| Michael Mendelsohn | Director | – |
| Simba Gill | Director | 34,061 |
| Stuart Duty | Director | – |
| Neil Gallagher | Director | – |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director | – |
| Ventures Opportunities Fund I. General Partner LLC Flagship | Director | 9,330,878 |
| Flagship Pioneering, LLC | Director | – |
| Flagship Ventures Fund V, L.P. | Director | – |
| Ventures Fund V. General Partner LLC Flagship | Director | – |
| Pioneering Fund VII General Partner LLC Flagship | Director | – |
| Flagship Pioneering Fund VII, L.P. | Director | – |
| Noubar Afeyan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Gottshalk | $2.36M | $3.07M | $1.17M | $84 | – |
| FY2024 Mr. Gottshalk | $1.56M | $2.38M | $1.68M | $73 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 106 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 24, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 23, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 19, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |